Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial

Journal:

The Lancet Diabetes & Endocrinology

Published:

2025-10-02

DOI:

10.1016/s2213-8587(25)00216-5

Affiliations:

8

Authors:

11

Go to article

Institutions	Authors	Share
Novo Nordisk, Denmark	4.125000	0.38
Inversago Pharma, Canada	2.125000	0.19
Tel Aviv University (TAU), Israel	1.125000	0.10
Weill Cornell Medicine, United States of America (USA)	1.125000	0.10
NIH National Institute on Alcohol Abuse and Alcoholism (NIAAA), United States of America (USA)	1.125000	0.10
Laval University (UL), Canada	0.916667	0.08
Groupe de Médecine de Famille Universitaire de Saint-Charles-Borromée, Canada	0.458333	0.04

Interested in Nutrition and Dietetics?